Compare NEPH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEPH | EVAX |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 32.7M |
| IPO Year | 2004 | 2020 |
| Metric | NEPH | EVAX |
|---|---|---|
| Price | $3.65 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 32.6K | 27.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1000.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $18,789,000.00 | N/A |
| Revenue This Year | $11.24 | N/A |
| Revenue Next Year | $11.58 | $328.20 |
| P/E Ratio | $369.50 | ★ N/A |
| Revenue Growth | ★ 32.67 | N/A |
| 52 Week Low | $2.66 | $2.11 |
| 52 Week High | $6.42 | $12.15 |
| Indicator | NEPH | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 47.58 |
| Support Level | $3.64 | $3.93 |
| Resistance Level | $3.78 | $4.65 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 85.23 | 28.98 |
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.